TY - JOUR T1 - Fluticasone propionate/formoterol fumarate improves asthma control and reduces exacerbations compared with fluticasone JF - European Respiratory Journal JO - Eur Respir J VL - 42 IS - Suppl 57 SP - P704 AU - Alberto Papi AU - David Price AU - Joaquin Sastre AU - Kirsten Kaiser AU - Mark Lomax AU - Tammy McIver AU - Sanjeeva Dissanayake Y1 - 2013/09/01 UR - http://erj.ersjournals.com/content/42/Suppl_57/P704.abstract N2 - Introduction: The combination of fluticasone (FLUT) and formoterol (FORM) in a single inhaler (FLUT/FORM; flutiform®) is approved for the maintenance treatment of asthma. This analysis assessed the efficacy of FLUT/FORM versus FLUT in patients who had previously received ICS therapy.Methods: Data were pooled from 5 randomized studies in patients with asthma (aged ≥12 years) treated for 8 or 12 weeks with FLUT/FORM (100/10, 250/10 or 500/20 μg b.i.d.; N=528) or FLUT alone (100, 250 or 500 μg b.i.d.; N=527).Results: FLUT/FORM significantly (p<0.05) improved lung function measures and increased the percentage of asthma control days (no symptoms, no rescue medication use and no sleep disturbance due to asthma) compared with FLUT (Table). The incidence and annualized rate of any exacerbation was significantly lower with FLUT/FORM.Conclusions: FLUT/FORM significantly improves lung function and asthma control measures, and is associated with a lower incidence of exacerbations compared with FLUT.View this table: ER -